https://doi.org/10.4081/hmr.v3i1.544

Innovative treatments: bexarotene

Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
Published: June 11, 2009
Abstract Views: 185
PDF: 320
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M Duvic
support@pagepress.org
There are now three FDA approved therapies for cutaneous T-cell lymphoma (CTCL) in the United States: denileukin diftitox (Ontak®, an interleukin (IL)-2 fusion protein, approved in 1998), bexarotene (Targretin®, the first retinoid-X receptor (RXR)-selective retinoid, approved in 1999), and vorinostat (a histone deacetylase inhibitor approved in 2006). These agents were approved based on Phase II clinical trials conducted in a limited number of CTCL patients. Treatment strategies in the management of MF are aimed at removal of the persistent antigen stimulus, reversal of the shift from Th2 to Th1 cytokine expression, inducing an increase in CD8+ cells, avoidance of immunosuppression, and prophylaxis or treatment of associated infectious complications. How best to integrate the new agents with existing therapies will require additional welldesigned, randomised trials. Our goal should be to produce rational combinations of drugs that can either induce a cure or prolonged complete responses in patients.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Duvic, M. (2009). Innovative treatments: bexarotene. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.544
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).